Abstract
Studies comparing systemic and salivary antibody responses against SARS-CoV-2 between children and adults show conflicting results. Besides, it is still unclear whether salivary antibody determination could be a non-invasive approach to evaluate the humoral immune response. In this work, we observed that salivary IgG antibody response against SARS-CoV-2 largely reflects the systemic response in vaccinated adults. Salivary and systemic antibody concentrations were higher in vaccinated adults who had been exposed, had schedules including mRNA-based vaccines, a greater number of exposures and a shorter time between last exposure and sample collection. Salivary antibody detection was associated with schedules including mRNA-based vaccines, time between last exposure and sample collection, and systemic antibody concentrations, suggesting that salivary antibodies might not be detectable in subjects with low systemic antibody levels. Comparison of antibody levels between vaccinated children and adults showed a stronger salivary antibody response against SARS-CoV-2 in children. This difference remained when antibody levels were compared between children and adults under similar conditions (vaccination schedules, number of exposures, time from last exposure). Multivariable linear regression analysis confirmed that age, symptomatic exposure, number of vaccine doses and schedules including mRNA-based vaccines were associated with salivary antibody levels (p<0.0001). Salivary antibody determination against SARS-CoV-2 could be a non-invasive approach to evaluate the short-term immune response in subjects with multiple exposures, especially when blood sampling cannot be performed. Knowledge of the underlying mechanisms that lead to the different local antibody response between children and adults, as well as their protective role in both groups, is required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant from CONICET (PIP 11220210100378CO).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local Ethics Committee of the Academia Nacional de Medicina
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos